AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Worlddrugtracker, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his PhD from ICT ,1991, Mumbai, India, in Organic chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA as ADVISOR earlier GLENMARK LS Research centre as consultant,Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Prior to joining Glenmark, he worked with major multinationals like Hoechst Marion Roussel, now sSanofi, Searle India ltd, now Rpg lifesciences, etc. he is now helping millions, has million hits on google on all organic chemistry websites. His New Drug Approvals, Green Chemistry International, Eurekamoments in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 year tenure, good knowledge of IPM, GMP, Regulatory aspects, he has several international drug patents published worldwide . He gas good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, polymorphism etc He suffered a paralytic stroke in dec 2007 and is bound to a wheelchair, this seems to have injected feul in him to help chemists around the world, he is more active than before and is pushing boundaries, he has one lakh connections on all networking sites, He makes himself available to all, contact him on +91 9323115463, [email protected]

Iclusig (ponatinib) VERSUS Gleevec (imatinib)

 drugs  Comments Off on Iclusig (ponatinib) VERSUS Gleevec (imatinib)
May 302013
 

3 Innovative Biotech Companies With Promising Cancer Therapies
Seeking Alpha
The global, Phase III EPIC trial which compares Iclusig to Novartis’ blockbuster drug Gleevec (imatinib) in patients with newly diagnosed CML, is advancing. The company expects to reach full patient enrollment in the fourth quarter of 2013

http://seekingalpha.com/article/1467241-3-innovative-biotech-companies-with-promising-cancer-therapies?source=google_news

 

Share
May 292013
 

 

3 Biopharma Runners With Fuel in the Tank
Investorplace.com
Gilead Sciences (GILD) stock recently set a new all-time high after reporting that in a recent Phase 2 study, its oral drug idelalisib successfully drove the life-threatening chronic lymphocytic leukemia (CLL) into remission. The regimen produced a 97%

 

Gilead Sciences (GILD) stock recently set a new all-time high after reporting that in a recent Phase 2 study, its oral drug idelalisib successfully drove the life-threatening chronic lymphocytic leukemia (CLL) into remission. The regimen produced a 97% response rate, with 93% of trial patients surviving progression-free at the end of two years. CLL, which produces too many mature white cells, is the second most common form of leukemia in the U.S.

http://investorplace.com/2013/05/3-biopharma-runners-with-fuel-in-the-tank/

Share

Researchers identify novel class of drugs for prostate cancers

 Uncategorized  Comments Off on Researchers identify novel class of drugs for prostate cancers
May 292013
 

Photo of Dr. Ganesh Raj, an associate professor of urology at UT Southwestern Medical Center.

http://www.sciencecodex.com/researchers_identify_novel_class_of_drugs_for_prostate_cancers-112935

(Photo Credit: UT Southwestern Medical Center)

Share

Omthera Fish-Oil Drug Hooks AstraZeneca in $323M Buyout

 drugs  Comments Off on Omthera Fish-Oil Drug Hooks AstraZeneca in $323M Buyout
May 292013
 

AstraZeneca plc’s planned buyout of Omthera Pharmaceuticals Inc. to gain Phase III-validated Epanova, the anti-triglyceride therapy based on ultra-pure fish oil, puts the firm at a “distinct commercial advantage” over Amarin Corp. plc, with its recently launched Vascepa (icosapent ethyl), said Decision Resources (DR) analyst Paramjit Narang.

http://www.bioworld.com/content/omthera-fish-oil-drug-hooks-astrazeneca-323m-buyout-0

Share

Bristol Myers Squibb Co.present data on its Phase 3 drug nivolumab, which is closest to reaching the market. (Its FDA approval is expected in late 2014 or early 2015.)

 Phase 3 drug  Comments Off on Bristol Myers Squibb Co.present data on its Phase 3 drug nivolumab, which is closest to reaching the market. (Its FDA approval is expected in late 2014 or early 2015.)
May 292013
 

Bristol Myers Squibb Co. (BMY), Gilead Sciences, Inc. (GILD), Halozyme
Insider Monkey (blog)
present data on its Phase 3 drug nivolumab, which is closest to reaching the market. (Its FDA approval is expected in late 2014 or early 2015.) Nivolumab has the potential to treat a vast array of cancers. At ASCO, Bristol Myers Squibb Co.

http://www.insidermonkey.com/blog/bristol-myers-squibb-co-bmy-gilead-sciences-inc-gild-halozyme-therapeutics-inc-halo-3-stocks-to-watch-ahead-of-asco-152583/

 

Bristol Myers Squibb Co. (NYSE:BMY) present data on its Phase 3 drug nivolumab, which is closest to reaching the market. (Its FDA approval is expected in late 2014 or early 2015.)

Nivolumab has the potential to treat a vast array of cancers. At ASCO, Bristol Myers Squibb Co. (NYSE:BMY) will be presenting data for a Phase 1 study of nivolumad combined with Yervoy to treat melanoma. In a 52-patient study, patients with advanced melanoma saw an overall tumor shrinkage rate of 40%.

However, the company’s most advanced study with nivolumab is in treating advanced non-small cell lung cancer. There, it produced an overall survival of 9.6 months, which is 30% better than standard-of-care. It’s also produced a 22-month overall survival rate in patients with advanced kidney cancer; compared to 20 months for the current standard of care

Share
May 282013
 

Slowing the aging process -- only with antibiotics

EPFL scientists have revealed the mechanism, hidden deep within cell mitochondria, that is responsible for making organisms age. Nematodes treated with antibiotics designed to disrupt this mechanism lived longer and healthier lives.

(Photo Credit: EPFLnews)

Slowing the aging process using only antibiotics 

 

READ ALL AT

http://www.kurzweilai.net/slowing-the-aging-process-using-only-antibiotics?utm_source=KurzweilAI+Daily+Newsletter&utm_campaign=b2bfdefdba-UA-946742-1&utm_medium=email&utm_term=0_6de721fb33-b2bfdefdba-282116853

Why is it that within a homogeneous population of the same species, some individuals live three times as long as others? EPFL researchers investigated this question and found the mechanism responsible for aging hidden deep within mitochondria. The were able to dramatically slow aging down in worms by administering antibiotics to the young, achieving a … more…
Share

Merrimack-completes-patient-enrollment-in-phase-2-breast-cancer-study

 drugs  Comments Off on Merrimack-completes-patient-enrollment-in-phase-2-breast-cancer-study
May 282013
 

read all at

http://clinicaltrials.pharmaceutical-business-review.com/news/merrimack-completes-patient-enrollment-in-phase-2-breast-cancer-study-240513

Share

Diabetes Drug To Be Sold As Weight Loss Medication Liraglutide (Victoza),

 drugs  Comments Off on Diabetes Drug To Be Sold As Weight Loss Medication Liraglutide (Victoza),
May 282013
 

File:Liraglutide structure.svg

liraglutide

Read all at Links

 

http://www.medicaldaily.com/articles/15910/20130526/diabetes-drug-sold-weight-loss-medication.htm

Danish pharmaceutical company Novo Nordisk announced plans to re-brand and sell its diabetes drug liraglutide (Victoza) as a weight loss drug for obese people by 2015. Currently, the drug is approved and sold to help regulate insulin production in people living with type 2 diabetes.

 

Share

Rapamycin Holdings Hopes To Exploit Commercial Potential Of UT Health Science Center Anti-Aging Drug Research

 phase 1  Comments Off on Rapamycin Holdings Hopes To Exploit Commercial Potential Of UT Health Science Center Anti-Aging Drug Research
May 282013
 

Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B cells by inhibiting their response to interleukin-2 (IL-2). Sirolimus is also used as a coronary stent coating.

A macrolide, sirolimus was discovered by Brazilian researchers as a product of the bacterium Streptomyces hygroscopicus in a soil sample from Easter Island — an island also known as Rapa Nui. It was approved by the FDA in September 1999 and is marketed under the trade name Rapamune by Pfizer (formerly by Wyeth).

Sirolimus was originally developed as an antifungal agent. However, this use was abandoned when it was discovered to have potent immunosuppressive and antiproliferative properties. It has since been shown to prolong the life of mice and might also be useful in the treatment of certain cancers.

Rapamycin Holdings Hopes To Exploit Commercial Potential Of UT Health

BioNews Texas
Rapamycin Holdings will be looking to raise an additional $6 million as it approaches the point of taking its first drug product to Phase 1 clinical trials. On December 7, 2012, Rapamycin Holdings Chief Executive Officer George Fillis announced that

read all at

http://bionews-tx.com/news/2013/05/27/rapamycin-holdings-hopes-to-exploit-commercial-potential-of-ut-health-science-center-anti-aging-drug-research/

Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: